62 completed, 23 terminated, 11 recruiting, 9 active not recruiting. 60 Phase 1, 44 Phase 2, 10 Phase 3, 4 Not applicable, 2 Early Phase 1.
Follow Anaplastic Astrocytoma: new trials by email Literature Review of Anaplastic Astrocytoma trials Research Report on Anaplastic Astrocytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas Bevacizumab-Containing Regimens, Non-Bevacizumab Regimens, BRAF ± MEK Targeted Therapy - Recurrent Malignant Glioma, Glioblastoma | Active not recruiting | Blokhin's Russian Cancer Research Center | 1000 | 2026-02-01 | 2026-03-04 | |
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2 - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Early Phase 1 | Recruiting | Nationwide Children's Hospital | 15 | 2025-08-03 | 2026-06-29 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Miami | 20 | 2025-06-19 | 2025-12-08 |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Ribociclib, Everolimus, Temozolomide (TMZ) - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-08-22 | 2026-05-29 |
| Targeted Pediatric High-Grade Glioma Therapy High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Recruiting | Nationwide Children's Hospital | 350 | 2024-08-02 | 2026-09-08 | |
| DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma DB107-RRV, DB107-FC - High Grade Glioma, Anaplastic Astrocytoma | Phase 2 | Recruiting | Ashish Shah | 33 | 2024-05-01 | 2026-05-28 |
| Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas PSMA PET-CT - Glioma, Astrocytoma | Not applicable | Unknown | All India Institute of Medical Sciences, Bhubaneswar | 35 | 2024-02-01 | 2024-02-08 |
| Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma Glioblastoma, Anaplastic Astrocytoma | Active not recruiting | Columbia University | 20 | 2024-01-30 | 2026-08-19 | |
| Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors Anaplastic Astrocytoma, Diffuse Brainstem Glioma | Terminated | Pediatric Brain Tumor Consortium | 57 | 2023-07-12 | 2026-04-23 | |
| A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma PCI 24781, Temozolomide - Recurrent High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Recruiting | University of Nebraska | 24 | 2023-06-26 | 2026-09-14 |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years - Medulloblastoma, Glioblastoma Multiforme | Phase 1 | Active not recruiting | Children's Oncology Group | 35 | 2022-07-01 | 2026-06-02 |
| Study of Pembrolizumab and M032 (NSC 733972) M032, Pembrolizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Alabama at Birmingham | 28 | 2022-02-25 | 2026-01-22 |
| Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection OS2966, Gadoteridol - Glioma, Malignant, High Grade Glioma | Phase 1 | Terminated | OncoSynergy, Inc. | 7 | 2021-03-02 | 2023-08-18 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms ONC206 - Central Nervous System Neoplasms, Glioblastoma | Phase 1 | Active not recruiting | Jazz Pharmaceuticals | 35 | 2020-10-26 | 2026-11-09 |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas INCB7839 - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 13 | 2020-07-27 | 2026-10-01 |
| Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture - Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2020-02-20 | 2026-11-12 |
| Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma Extended Release Flucytosine, NovoTTF-100A Device, Quality-of-Life Assessment - Anaplastic Astrocytoma, Glioblastoma | Phase 2 / Phase 3 | Withdrawn | NRG Oncology | 2020-01-31 | 2026-05-07 | |
| Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg - High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2019-12-06 | 2023-10-06 |
| Pediatric Long-Term Follow-up and Rollover Study dabrafenib, trametinib - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 163 | 2019-11-04 | 2026-08-27 |
| Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG Encorafenib, Binimetinib, Research Bloods - High Grade Glioma, BRAF V600E | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 5 | 2019-07-29 | 2024-10-31 |
Showing 20 of 122. Sign in to see all of them.
Astrocytoma (122) · Glioblastoma (113) · Glioma (79) · Oligodendroglioma (55) · Brain Neoplasms (46) · Gliosarcoma (32) · Diffuse Intrinsic Pontine Glioma (14) · Ependymoma (12) · Neoplasms (12) · Medulloblastoma (9) · Recurrence (7) · Central Nervous System Neoplasms (6) · Neuroectodermal Tumors, Primitive (6) · Meningioma (5) · Neoplasms, Neuroepithelial (4)
Neoplasms by Histologic Type (122) · Neoplasms, Glandular and Epithelial (122) · Neoplasms, Nerve Tissue (122) · Neuroectodermal Tumors (121) · Neoplasms, Germ Cell and Embryonal (120) · Neoplasms, Neuroepithelial (118) · Neoplasms (110) · Neoplasms by Site (67) · Nervous System Diseases (66) · Nervous System Neoplasms (66) · Central Nervous System Diseases (62) · Brain Diseases (61) · Central Nervous System Neoplasms (59) · Glioma (43) · Infratentorial Neoplasms (16)
Temozolomide (20) · Bevacizumab (9) · Radiotherapy (9) · Surgical Procedures, Operative (6) · Flucytosine (5) · IL13-PE38 (5) · Lomustine (5) · Radiation (5) · Carboplatin (4) · Carmustine (4) · Magnetic Resonance Spectroscopy (4) · Radiotherapy, Intensity-Modulated (4) · trametinib (4) · vocimagene amiretrorepvec (4) · Cetuximab (3)
National Cancer Institute (NCI) (12) · Northwell Health (7) · INSYS Therapeutics Inc (5) · Pediatric Brain Tumor Consortium (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Tocagen Inc. (4) · Children's Oncology Group (3) · Nationwide Children's Hospital (3) · Candel Therapeutics, Inc. (2) · Isarna Therapeutics GmbH (2) · Jonsson Comprehensive Cancer Center (2) · NRG Oncology (2) · Novartis Pharmaceuticals (2) · Roswell Park Cancer Institute (2) · Shandong Lanjin Pharmaceuticals Co.,Ltd (2)
United States (100) · Canada (13) · Germany (12) · Australia (7) · France (6) · Netherlands (6) · United Kingdom (6) · Israel (5) · Russia (5) · China (4) · Italy (4) · New Zealand (4) · Argentina (3) · Belgium (3) · Brazil (3)
John Boockvar, MD (5) · Asha Das, MD (3) · Katherine E Warren, M.D. (3) · Maryam Fouladi, MD (3) · Annick Desjardins, MD (2) · E. Antonio Chiocca, MD, PhD (2) · Margot Lazow, MD (2) · Stuart A Grossman, MD (2) · Alexandra Miller, MD, PhD (1) · Amy L Bredlau, MD (1) · Andrew B. Lassman, MD (1) · Andrew Cluster, M.D. (1) · Arti B Gaur, PhD (1) · Ashish Shah, MD (1)
PMID 34331515, PMID 12749708, PMID 15809479, PMID 16877732, PMID 17429084, PMID 20725730, PMID 21242491, PMID 21844505, PMID 22578793, PMID 24786603, PMID 25098701, PMID 25338318, PMID 26843484, PMID 26860632, PMID 27252174, PMID 27370396, PMID 28690586, PMID 29762717, PMID 30151703, PMID 31795071, PMID 32009149, PMID 32064499, PMID 32285998, PMID 33119048, PMID 33571520, PMID 33838625, PMID 34142085, PMID 34214495, PMID 34359048, PMID 34943910, PMID 35417530, PMID 36006068, PMID 36705923, PMID 37004712, PMID 37610803, PMID 37643378, PMID 37733309, PMID 37790490, PMID 38182653, PMID 38215438, PMID 38216554, PMID 38719809, PMID 39560182, PMID 40132910, PMID 40225909, PMID 41325560, PMID 41740060, PMID 9390198
UM1CA081457 (4), U01CA081457 (3), U10CA180886 (3), UM1CA137443 (3), 2015 (2), P30CA016056 (2), U10CA098543 (2), U10CA180868 (2), UM1CA097452 (2), 2023 (1), P30CA015083 (1), P30CA036727 (1), P50CA108961 (1), P50CA221747 (1), R01CA125244 (1)